BRABEVACNOR1
BRABEVACNOR1
AMBEV S/A ON
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 246.51B EUR | 251.73B EUR | 237.85B EUR | 216.45B EUR |
Enterprise Value | 234.75B EUR | 238.06B EUR | 222.96B EUR | 201.19B EUR |
Valuation Multiples | ||||
Trailing P/E | 15.52x | 15.49x | 15.27x | 18.33x |
Forward P/E | 14.21x | -- | -- | -- |
Price to Sales | 2.79x | 2.85x | 2.7x | 3.29x |
Price to Book | 2.8x | 2.85x | 2.64x | 2.46x |
EV/Revenue | 2.66x | 2.7x | 2.53x | 3.06x |
EV/EBITDA | 8.76x | 7.53x | 7.1x | 8.56x |
Price to FCF (P/FCF) | 12.41x | 10.48x | 10.74x | 11.12x |
EV/FCF | 11.82x | 9.91x | 10.06x | 10.34x |
FCF Yield | 8.06% | 9.54% | 9.31% | 8.99% |